ZyVersa Therapeutics (ZVSA) Competitors $0.67 -0.03 (-4.00%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.67 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVSA vs. EYEN, ALVR, ATHA, IBIO, EQ, CTXR, BGXX, PHIO, BCDA, and PHXMShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Eyenovia (EYEN), AlloVir (ALVR), Athira Pharma (ATHA), iBio (IBIO), Equillium (EQ), Citius Pharmaceuticals (CTXR), Bright Green (BGXX), Phio Pharmaceuticals (PHIO), BioCardia (BCDA), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Its Competitors Eyenovia AlloVir Athira Pharma iBio Equillium Citius Pharmaceuticals Bright Green Phio Pharmaceuticals BioCardia PHAXIAM Therapeutics ZyVersa Therapeutics (NASDAQ:ZVSA) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability. Does the media refer more to ZVSA or EYEN? In the previous week, Eyenovia had 6 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 6 mentions for Eyenovia and 0 mentions for ZyVersa Therapeutics. Eyenovia's average media sentiment score of 0.34 beat ZyVersa Therapeutics' score of 0.00 indicating that Eyenovia is being referred to more favorably in the news media. Company Overall Sentiment ZyVersa Therapeutics Neutral Eyenovia Neutral Which has stronger valuation and earnings, ZVSA or EYEN? ZyVersa Therapeutics has higher earnings, but lower revenue than Eyenovia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZyVersa TherapeuticsN/AN/A-$9.41MN/AN/AEyenovia$60K766.08-$49.82M-$58.40-0.27 Is ZVSA or EYEN more profitable? ZyVersa Therapeutics has a net margin of 0.00% compared to Eyenovia's net margin of -62,238.41%. Eyenovia's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ZyVersa TherapeuticsN/A -109.54% -43.95% Eyenovia -62,238.41%N/A -316.90% Which has more volatility and risk, ZVSA or EYEN? ZyVersa Therapeutics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Do analysts recommend ZVSA or EYEN? Eyenovia has a consensus price target of $2.00, suggesting a potential downside of 87.47%. Given Eyenovia's stronger consensus rating and higher possible upside, analysts plainly believe Eyenovia is more favorable than ZyVersa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Eyenovia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders hold more shares of ZVSA or EYEN? 3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Eyenovia shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 7.1% of Eyenovia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryEyenovia beats ZyVersa Therapeutics on 9 of the 12 factors compared between the two stocks. Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.20M$2.91B$5.55B$9.04BDividend YieldN/A2.44%5.22%4.00%P/E RatioN/A21.5627.6420.24Price / SalesN/A275.02417.15117.30Price / CashN/A42.7336.8958.10Price / Book0.207.518.035.67Net Income-$9.41M-$55.14M$3.18B$249.21M7 Day Performance-5.67%4.61%2.93%3.28%1 Month Performance2.61%0.90%1.72%3.95%1 Year Performance-81.67%5.40%34.39%20.98% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics0.5853 of 5 stars$0.67-4.0%N/A-81.7%$3.20MN/A0.002EYENEyenovia2.6176 of 5 stars$5.48+30.2%$2.00-63.5%-77.1%$12.14M$60K-0.0940Analyst UpgradeHigh Trading VolumeALVRAlloVirN/A$2.40-6.6%N/A-84.5%$12.10MN/A-0.12110Gap UpHigh Trading VolumeATHAAthira Pharma2.7364 of 5 stars$0.30-2.3%$11.25+3,700.7%-87.0%$11.83MN/A-0.1440Gap DownIBIOiBio2.1079 of 5 stars$0.71-7.6%$4.30+503.6%-61.1%$11.77M$375K0.00100High Trading VolumeEQEquillium1.8169 of 5 stars$0.29-11.3%$3.00+934.5%-51.9%$11.68M$41.10M-0.7440Gap UpCTXRCitius Pharmaceuticals2.1457 of 5 stars$1.03-4.6%$54.50+5,191.3%-83.4%$11.48MN/A0.0020High Trading VolumeBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownPHIOPhio Pharmaceuticals2.1947 of 5 stars$2.18-4.0%$14.00+542.2%-51.4%$10.87MN/A-0.2010Gap DownBCDABioCardia3.9884 of 5 stars$2.02-2.9%$25.00+1,137.6%-29.0%$10.77M$3K-0.8740News CoverageInsider TradePHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049 Related Companies and Tools Related Companies EYEN Alternatives ALVR Alternatives ATHA Alternatives IBIO Alternatives EQ Alternatives CTXR Alternatives BGXX Alternatives PHIO Alternatives BCDA Alternatives PHXM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVSA) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
